[go: up one dir, main page]

WO2007065024A3 - Composition and use of phyto-percolate for treatment of disease - Google Patents

Composition and use of phyto-percolate for treatment of disease Download PDF

Info

Publication number
WO2007065024A3
WO2007065024A3 PCT/US2006/046320 US2006046320W WO2007065024A3 WO 2007065024 A3 WO2007065024 A3 WO 2007065024A3 US 2006046320 W US2006046320 W US 2006046320W WO 2007065024 A3 WO2007065024 A3 WO 2007065024A3
Authority
WO
WIPO (PCT)
Prior art keywords
phyto
percolate
disease
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/046320
Other languages
French (fr)
Other versions
WO2007065024A2 (en
Inventor
Tiffany Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zivo Bioscience Inc
Original Assignee
Health Enhancement Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Enhancement Products Inc filed Critical Health Enhancement Products Inc
Priority to CA2631773A priority Critical patent/CA2631773C/en
Priority to JP2008543545A priority patent/JP2009518312A/en
Priority to AU2006320264A priority patent/AU2006320264A1/en
Priority to EP06838974A priority patent/EP1954800A4/en
Publication of WO2007065024A2 publication Critical patent/WO2007065024A2/en
Publication of WO2007065024A3 publication Critical patent/WO2007065024A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The phyto-percolate is believed to contain an enzyme having proteolytic activity. The invention further relates to the use of the phyto-percolate in a variety of disease states.
PCT/US2006/046320 2005-04-20 2006-12-04 Composition and use of phyto-percolate for treatment of disease Ceased WO2007065024A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2631773A CA2631773C (en) 2005-12-02 2006-12-04 Composition and use of phyto-percolate for treatment of disease
JP2008543545A JP2009518312A (en) 2005-12-02 2006-12-04 Compositions and uses of plant exudates for treating diseases
AU2006320264A AU2006320264A1 (en) 2005-04-20 2006-12-04 Composition and use of phyto-percolate for treatment of disease
EP06838974A EP1954800A4 (en) 2005-12-02 2006-12-04 Composition and use of phyto-percolate for treatment of disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74177405P 2005-12-02 2005-12-02
US60/741,774 2005-12-02

Publications (2)

Publication Number Publication Date
WO2007065024A2 WO2007065024A2 (en) 2007-06-07
WO2007065024A3 true WO2007065024A3 (en) 2008-01-10

Family

ID=38092904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046320 Ceased WO2007065024A2 (en) 2005-04-20 2006-12-04 Composition and use of phyto-percolate for treatment of disease

Country Status (5)

Country Link
EP (1) EP1954800A4 (en)
JP (1) JP2009518312A (en)
AU (1) AU2006320264A1 (en)
CA (1) CA2631773C (en)
WO (1) WO2007065024A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807622B2 (en) 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
US8586053B2 (en) 2005-09-21 2013-11-19 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
EP2501390A4 (en) * 2009-11-16 2014-07-02 Health Enhancement Products Inc Composition and methods for affecting cytokines and nf-kb
CA2827401A1 (en) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents and mechanisms for treating hypercholesterolemia
WO2014167326A1 (en) * 2013-04-09 2014-10-16 Cresset Biomolecular Discovery Ltd The local treatment of inflammatory ophthalmic diseases
US10232028B2 (en) 2013-06-13 2019-03-19 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
ES2972377T3 (en) 2015-02-16 2024-06-12 Zivo Bioscience Inc Anti-inflammatory and immunomodulatory compositions comprising Klebsormidium and uses thereof
WO2017142906A1 (en) 2016-02-16 2017-08-24 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030152587A1 (en) * 2000-08-10 2003-08-14 Kralovec Jaroslav A. Methods for making and using a Chlorella extract having immunomodulating properties
WO2005112987A2 (en) * 2004-04-23 2005-12-01 Health Enhancement Products, Inc. Method of preparation and use of fibrinolytic enzymes in the treatment of disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030152587A1 (en) * 2000-08-10 2003-08-14 Kralovec Jaroslav A. Methods for making and using a Chlorella extract having immunomodulating properties
WO2005112987A2 (en) * 2004-04-23 2005-12-01 Health Enhancement Products, Inc. Method of preparation and use of fibrinolytic enzymes in the treatment of disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM ET AL.: "Purification and characterization of a fibrinolytic enzyme produced from Bacillus sp. strain CK 11-4 screened from Chungkook-Jang", APPL. ENVIRON. MICROBIOLOGY, vol. 62, no. 7, July 1996 (1996-07-01), pages 2482 - 2488, XP007908743 *

Also Published As

Publication number Publication date
AU2006320264A1 (en) 2007-06-07
WO2007065024A2 (en) 2007-06-07
CA2631773C (en) 2022-04-26
CA2631773A1 (en) 2007-06-07
JP2009518312A (en) 2009-05-07
EP1954800A4 (en) 2010-03-03
EP1954800A2 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
WO2008057459A3 (en) Antagonists of pcsk9
WO2008057458A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
WO2006029183A3 (en) Compositions and methods for the diagnosis and treatment of tumor
SI1791791T1 (en) Methods and compositions for treatment of water
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2007001851A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005077093A3 (en) Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
WO2007087259A3 (en) Enzyme and photobleach containing compositions
WO2005000860A3 (en) Compositions and methods for treatment of disease with acetylated disaccharides
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
WO2005113752A3 (en) Methods and compositions for producing germ cells from peripheral blood derived germline stem cells
WO2007065024A3 (en) Composition and use of phyto-percolate for treatment of disease
WO2005112987A3 (en) Method of preparation and use of fibrinolytic enzymes in the treatment of disease
WO2007117559A3 (en) Renin inhibitors
WO2005005481A3 (en) Combination therapy for gastroenteric diseases caused by microorganisms
WO2006114105A3 (en) Use of modified factor vii for treating bleeding
WO2004096124A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004093563A3 (en) Low cholesterol, functional animal muscle protein composition and process
WO2006113925A3 (en) Composition and use of phyto-percolate for treatment of disease
WO2007038627A3 (en) Stabilized antimicrobial compositions and related methods of preparation
WO2006081516A3 (en) USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008543545

Country of ref document: JP

Ref document number: 2631773

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006838974

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006320264

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006320264

Country of ref document: AU

Date of ref document: 20061204

Kind code of ref document: A